Skip to main content

Parkinson's Disease clinical trials at UCSF
19 in progress, 5 open to eligible people

  • Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease

    open to eligible people ages 40-80

    To evaluate the dose-related safety of BIIB054, to evaluate the pharmacodynamic effects of BIIB054 on the integrity of nigrostriatal dopaminergic nerve terminals, to assess the pharmacokinetic (PK) profile of BIIB054 and to evaluate the immunogenicity of BIIB054.

    San Francisco, California and other locations

  • Microbiota Intervention to Change the Response of Parkinson's Disease

    open to eligible people ages 30 years and up

    The clinical phenotype of Parkinson's disease (PD) is quite variable, as is the response to and side effects from medications. While many patients respond to carbidopa/levodopa early on, motor fluctuations and dyskinesias can become a problem as the condition progresses, causing significant impairment in function and quality of life. The gut microbiome is of increasing interest in PD, potentially contributing to pathophysiology and clinical phenotype. Furthermore, gut bacteria are capable of metabolizing levodopa, which may decrease its ability to reach the central nervous system and could explain the variable effect seen clinically. Altering the population of drug-metabolizing bacteria could improve the clinical symptoms of PD and the benefit seen with medications. The investigators hypothesize that the gut microbiome in people with PD correlates with their phenotypic characteristics, which can be improved with targeting the microbiome through dietary or therapeutic interventions. The investigators propose a two-part clinical trial. First, a cross-sectional analysis will correlate the microbiome profile with (a) the clinical phenotype of PD and (b) medication response. Second, a randomized, controlled trial, will evaluate the effect of microbiome manipulation on clinical phenotype and medication response. The investigators plan to reduce the level of bacteria through antibiotic use, resetting the potentially disadvantageous microbiome population. Outcomes will include changes in clinical symptoms, alterations in the the microbiome, and changes in serum markers of inflammation. This thorough characterization will broaden our understanding of the gut-brain axis significantly in PD in clinically relevant ways that have yet to be explored.

    San Francisco, California

  • More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease

    open to eligible people ages 18-105

    This is a two-center (University of Colorado, University of California San Francisco) community-based comparative effectiveness study of outpatient palliative care for Parkinson's disease (PD) and related disorders (progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), multiple systems atrophy (MSA), Lewy Body Dementia (LBD). It will utilize a randomized stepped-wedge design to compare patient and caregiver outcomes between usual care in the community versus usual care augmented by palliative training and telemedicine support to provide other resources (e.g. social work).

    San Francisco, California and other locations

  • The Motor Network in Parkinson's Disease: Mechanisms of Therapy

    open to eligible people ages 21-75

    This is an exploratory pilot study to identify neural correlates of specific motor signs in Parkinson's disease (PD) and dystonia, using a novel totally implanted neural interface that senses brain activity as well as delivering therapeutic stimulation. Parkinson's disease and isolated dystonia patients will be implanted unilaterally or bilaterally with a totally internalized bidirectional neural interface, Medtronic Summit RC+S. This study includes three populations: ten PD patients undergoing deep brain stimulation in the subthalamic nucleus (STN), ten PD patients with a globus pallidus (GPi) target and five dystonia patients. All groups will test a variety of strategies for feedback-controlled deep brain stimulation. Only the STN patients will undergo a blinded, small pilot clinical trial of closed-loop stimulation for thirty days.

    San Francisco, California

  • VY-AADC02 for Parkinson's Disease With Motor Fluctuations

    open to eligible people ages 40-75

    The objectives of this study are to assess the distribution, efficacy, and safety of VY-AADC02 in Patients with Parkinson's Disease with Motor Fluctuations.

    San Francisco, California and other locations

  • A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease

    Sorry, in progress, not accepting new patients

    This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhibitors since baseline. The study will consist of 2 parts: a 52-week, double-blind, placebo-controlled treatment period (Part 1) after which eligible participants will continue into an all-participants-on-treatment blinded dose extension for an additional 52 weeks (Part 2).

    San Francisco, California and other locations

  • Chronic Effects of DBS in Parkinson's Disease and Dystonia

    Sorry, in progress, not accepting new patients

    The purpose of this study is to use an investigational device to record brain activity for 12-24 months following surgical implantation of deep brain stimulation (DBS) systems. The goal of the study is better understanding of brain activity in movement disorders and how they relate to DBS, not to bring new devices to market.

    San Francisco, California

  • Cortical Stimulation to Treat Mood and Behavioral Symptoms in Parkinson's Disease Patients

    Sorry, in progress, not accepting new patients

    This study will investigate cortical stimulation to treat mood and behavioral symptoms in Parkinson's disease patients.

    San Francisco, California

  • Does Outpatient Palliative Care Improve Patient-centered Outcomes in Parkinson's Disease?

    Sorry, in progress, not accepting new patients

    The purpose of this study is to improve outcomes for persons living with Parkinson's Disease (PD) and their family caregivers. The investigators hypothesize that outpatient interdisciplinary palliative care will improve patient-centered outcomes for PD patients at high-risk for poor outcomes.

    San Francisco, California and other locations

  • Efficacy of Isradipine in Early Parkinson Disease

    Sorry, in progress, not accepting new patients

    The purpose of the study is to determine whether treatment with isradipine is effective in slowing the progression of Parkinson disease disability.

    San Francisco, California and other locations

  • Mindfulness-based Cognitive Therapy (MBCT) for People With Parkinson's Disease

    Sorry, not yet accepting patients

    This study aims to explore the feasibility and effectiveness of mindfulness-based cognitive therapy (MBCT) in reducing anxiety and/or depressive symptoms in people with Parkinson's disease.

    San Francisco, California

  • Observational, Long-term, Extension Study for Participants of Prior VY-AADC01 or VY-AADC02 Studies

    Sorry, accepting new patients by invitation only

    An extension study for participants who have completed VY-AADC01 or VY-AADC02 Studies

    San Francisco, California

  • Safety and Biomarker Study of EPI-589 in Parkinson's Disease

    Sorry, in progress, not accepting new patients

    Open-label study with 30-day run-in phase and adaptive design component to include more subjects if deemed appropriate by investigators.

    San Francisco, California and other locations

  • Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease

    Sorry, in progress, not accepting new patients

    Safety and efficacy of AADC gene transfer in participants with Parkinson's disease.

    San Francisco, California and other locations

  • Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease

    Sorry, in progress, not accepting new patients

    Safety study of AADC gene transfer (VY-AADC01) in subjects with Parkinson's disease.

    San Francisco, California and other locations

  • Study of Urate Elevation in Parkinson's Disease, Phase 3

    Sorry, in progress, not accepting new patients

    A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial to determine whether oral inosine dosed to moderately elevate serum urate (from ≤5.7 mg/dL to 7.1-8.0 mg/dL) over 2 years slows clinical decline in early PD. Clinical decline will be assessed as change in the primary outcome variable of the Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), a composite scale comprising patient- and clinician-reported outcomes.

    San Francisco, California and other locations

  • Trial of Parkinson's And Zoledronic Acid

    Sorry, not yet accepting patients

    This study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 65 years and older with Parkinson's Disease with 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.

  • Use of Interventional MRI for Implantation of Deep Brain Stimulator Electrodes

    Sorry, accepting new patients by invitation only

    The purpose of this study is to gather observational data on an already FDA-approved implantation technique for deep brain stimulation (DBS) in which the entire surgery is performed within an MRI scanner ("interventional MRI", or iMRI). With this surgical technique, the patient is fully asleep (under general anesthesia) during DBS implantation. The standard method for the placement of deep brain stimulators does not use MRI during the actual DBS placement. The standard method involves placement of a rigid frame on the patient's head, performance of a short MRI scan, transport to the operating room, placement of the DBS electrodes in the operating room, and return to the MRI suite for another MR to confirm correct electrode placement. In the standard method, the patient must be awake for 2-4 hours in the operating room to have "brain mapping" performed, where the brain target is confirmed by passing "microelectrodes" (thin wires) into the brain to record its electrical activity. In the standard method, general anesthesia is not required. With the iMRI technique, the surgery is guided entirely by MRI images performed multiple times as the DBS electrode is advanced. This eliminates the need for the patient to be awake, and eliminates the need for passing microelectrodes into the brain before placing the permanent DBS electrode.

    San Francisco, California

  • Wearable Assessments in the Clinic and Home in PD

    Sorry, not currently recruiting here

    The purpose of this study is to evaluate disease progression in persons with early Parkinson disease, as assessed by digital and electronic sensor data collection to be correlated with typical clinical assessments.

    San Francisco, California and other locations

Last updated: